» Articles » PMID: 19903920

Major Lipids, Apolipoproteins, and Risk of Vascular Disease

Abstract

Context: Associations of major lipids and apolipoproteins with the risk of vascular disease have not been reliably quantified.

Objective: To assess major lipids and apolipoproteins in vascular risk.

Design, Setting, And Participants: Individual records were supplied on 302,430 people without initial vascular disease from 68 long-term prospective studies, mostly in Europe and North America. During 2.79 million person-years of follow-up, there were 8857 nonfatal myocardial infarctions, 3928 coronary heart disease [CHD] deaths, 2534 ischemic strokes, 513 hemorrhagic strokes, and 2536 unclassified strokes.

Main Outcome Measures: Hazard ratios (HRs), adjusted for several conventional factors, were calculated for 1-SD higher values: 0.52 log(e) triglyceride, 15 mg/dL high-density lipoprotein cholesterol (HDL-C), 43 mg/dL non-HDL-C, 29 mg/dL apolipoprotein AI, 29 mg/dL apolipoprotein B, and 33 mg/dL directly measured low-density lipoprotein cholesterol (LDL-C). Within-study regression analyses were adjusted for within-person variation and combined using meta-analysis.

Results: The rates of CHD per 1000 person-years in the bottom and top thirds of baseline lipid distributions, respectively, were 2.6 and 6.2 with triglyceride, 6.4 and 2.4 with HDL-C, and 2.3 and 6.7 with non-HDL-C. Adjusted HRs for CHD were 0.99 (95% CI, 0.94-1.05) with triglyceride, 0.78 (95% CI, 0.74-0.82) with HDL-C, and 1.50 (95% CI, 1.39-1.61) with non-HDL-C. Hazard ratios were at least as strong in participants who did not fast as in those who did. The HR for CHD was 0.35 (95% CI, 0.30-0.42) with a combination of 80 mg/dL lower non-HDL-C and 15 mg/dL higher HDL-C. For the subset with apolipoproteins or directly measured LDL-C, HRs were 1.50 (95% CI, 1.38-1.62) with the ratio non-HDL-C/HDL-C, 1.49 (95% CI, 1.39-1.60) with the ratio apo B/apo AI, 1.42 (95% CI, 1.06-1.91) with non-HDL-C, and 1.38 (95% CI, 1.09-1.73) with directly measured LDL-C. Hazard ratios for ischemic stroke were 1.02 (95% CI, 0.94-1.11) with triglyceride, 0.93 (95% CI, 0.84-1.02) with HDL-C, and 1.12 (95% CI, 1.04-1.20) with non-HDL-C.

Conclusion: Lipid assessment in vascular disease can be simplified by measurement of either total and HDL cholesterol levels or apolipoproteins without the need to fast and without regard to triglyceride.

Citing Articles

Beyond platelet activation: dysregulated lipid metabolism in defining risk and pathophysiology of VITT.

Stevens H, McFadyen J, Mellett N, Lynn D, Duong T, Giles C Res Pract Thromb Haemost. 2025; 9(1):102677.

PMID: 40041449 PMC: 11879676. DOI: 10.1016/j.rpth.2025.102677.


Repeated-Dose Toxicity of Lauric Acid and Its Preventive Effect Against Tracheal Hyper-Responsiveness in Wistar Rats with Possible Molecular Targets.

Figueiredo I, Martins A, Cavalcanti A, Fernandes J, Gomes L, Vieira M Pharmaceuticals (Basel). 2025; 18(2).

PMID: 40006035 PMC: 11859213. DOI: 10.3390/ph18020221.


Novel lipid profiles and atherosclerotic cardiovascular disease risk: insights from a latent profile analysis.

Wan H, Wu H, Wei Y, Wang S, Ji Y Lipids Health Dis. 2025; 24(1):71.

PMID: 40001219 PMC: 11854406. DOI: 10.1186/s12944-025-02471-3.


Epigenetic regulation in coronary artery disease: from mechanisms to emerging therapies.

Gao R, Liu M, Yang H, Shen Y, Xia N Front Mol Biosci. 2025; 12:1548355.

PMID: 39959304 PMC: 11825346. DOI: 10.3389/fmolb.2025.1548355.


Development and validation of a predictive model for carotid atherosclerosis in postmenopausal women.

Liu J, Zeng X, Ruan J, Kang Y, Lu Y, Li S Sci Rep. 2025; 15(1):5079.

PMID: 39934244 PMC: 11814320. DOI: 10.1038/s41598-025-89098-7.


References
1.
Nordestgaard B, Benn M, Schnohr P, Tybjaerg-Hansen A . Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA. 2007; 298(3):299-308. DOI: 10.1001/jama.298.3.299. View

2.
Freiberg J, Tybjaerg-Hansen A, Skov Jensen J, Nordestgaard B . Nonfasting triglycerides and risk of ischemic stroke in the general population. JAMA. 2008; 300(18):2142-52. DOI: 10.1001/jama.2008.621. View

3.
Barter P, Caulfield M, Eriksson M, Grundy S, Kastelein J, Komajda M . Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007; 357(21):2109-22. DOI: 10.1056/NEJMoa0706628. View

4.
Frikke-Schmidt R, Nordestgaard B, Stene M, Sethi A, Remaley A, Schnohr P . Association of loss-of-function mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease. JAMA. 2008; 299(21):2524-32. DOI: 10.1001/jama.299.21.2524. View

5.
Pearson T, Blair S, Daniels S, Eckel R, Fair J, Fortmann S . AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association.... Circulation. 2002; 106(3):388-91. DOI: 10.1161/01.cir.0000020190.45892.75. View